OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Sunday morning. The firm issued a sell rating on the stock. Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a report on Tuesday, October 15th. One […]
31 Oct 02:46 · The Cerbat Gem